Athens, Greece - A dose-response study of the ACE-inhibitor enalapril (Vasotec® - Merck) in congestive heart failure (CHF) patients found no difference in survival and clinical status in patients ...

Please provide your email address to receive an email when new articles are posted on . Enalapril was not superior to standard care for preventing chemotherapy-related cardiotoxicity for breast cancer ...

These recommendations will probably be reinforced in future guidelines, on the basis of the Valsartan Antihypertensive Long-term Use Evaluation trial, which showed that patients whose BP was ...

Combined treatment with enalapril and carvedilol may prevent chemotherapy-induced left ventricular systolic dysfunction in patients with hematological malignancies, according to findings from the ...